COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY. (June 2017) - Tam, C.S.; Roberts, A.W.; Anderson, M.; Dawson, S.; Hicks, R.; Burbury, K.; Turner, G.; Di Iulio, J.; Bressel, M.; Westerman, D.; Agarwal, R.; Pott, C.; et al.